On 5 December, the webinar on “The Price of Success: Can Innovative Payment Models Support Access to Combination Therapies in Europe?” hosted by the Office of Health Economics (OHE), brought together healthcare experts and stakeholders to explore how new approaches to pricing and payment could enhance access to life-saving combination therapies for patients, particularly those battling cancer.
The webinar featured a diverse range of expert speakers, each offering valuable perspectives on the topic. Stan Jackson, Global Public Affairs Lead in Oncology at Astellas Pharma, discussed the challenges of bringing combination therapies to market in oncology, highlighting issues such as outdated healthcare systems designed for monotherapies and the difficulty in fairly appraising the value of combined treatments. Carol Longson, an independent advisor, explained that while the issue of innovative payment models for combination therapies was not new, it had become more urgent as oncology increasingly shifted toward combination treatments. Professor Claudio Jeremy, an expert in management, shared insights from Italy’s experience with innovative pricing models and discussed how both academic and institutional research have contributed to the development of these models for combination therapies. Antonella Cardone, CEO of Cancer Patients Europe, provided the patients’ perspective on this critical issue and emphasised the importance of combination therapies in cancer treatment, highlighting several key benefits. These therapies help overcome drug resistance by using drugs with different mechanisms of action.
The panel discussion focused on the challenges and potential solutions for pricing combination therapies. Stan emphasised the complexity of pricing due to varying European evaluation systems but expressed optimism that solutions could be found with political will. Carol highlighted the need for procedural rules that allow flexibility without disrupting pricing consistency. Antonella advocated for value-based pricing models that reflect the long-term benefits of treatments. Claudio stressed the importance of a common framework and collaboration to align value and affordability.
The panel concluded with a call for multi-stakeholder collaboration, particularly in creating clearer negotiation pathways for companies involved in combination therapies.

